Home > Oncology > BCC 2019 > St. Gallen Consensus > Adjuvant Her2-targeted therapy

Adjuvant Her2-targeted therapy


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
10:31:46pm> hello nurse from conference
Trial
APHINITY
For patients with Her2-positive early breast cancer, the standard management includes adjuvant chemotherapy plus Her2-targeted therapy. At the St. Gallen Conference 2019, the panel zoomed in on specific subtypes of Her2-positive early breast cancer. A small majority of the panellists (55%) took the view that Her2-targeted therapy is not required for patients with Her2-positive, T1a, node-negative breast cancer, while 43% of the panellists voted in favour of Her2-targeted therapy for these patients. A majority of 62% of the panellists stated that ER-status does not affects this opinion, while 28% of the panellists stated that ER-status will affect their decision on Her2-targeted adjuvant therapy. In line with the previous questions, 52% of the panellists indicated that for patients with ER-positive, Her2-positive breast cancer, addition of pertuzumab to the adjuvant treatment is not a standard therapy. The preferred regimen for adjuvant therapy in patients with stage 1 Her2...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on